Loading...
Pulmonx reported a 35% increase in worldwide revenue to $14.5 million for the first quarter of 2023, with U.S. revenue increasing by 55%. The company's gross margin was 73%.
Worldwide revenue increased by 35% to $14.5 million.
U.S. revenue increased by 55%.
Gross margin was 73%.
15 new U.S. treatment centers for Zephyr Valves were added.
Pulmonx expects full year 2023 revenue to be in the range of $63 million to $65 million and gross margin to be in the range of 73% to 74%. Total operating expenses are expected to be in the range of $112 million to $114 million.
Analyze how earnings announcements historically affect stock price performance